AMRA-MEDICAL
2.5.2024 15:36:33 CEST | Business Wire | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/
Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher
The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the primary objective of assessing change in thigh muscle fat infiltration due to treatment intervention over a 40-week period. Participants were also assessed for the exploratory outcome of adverse muscle composition, defined as high muscle fat infiltration and low muscle volume z-score.
Among the 128 participants, median muscle fat infiltration at baseline was 7.8%. The study found that liraglutide significantly reduced muscle fat infiltration when compared to placebo. The mean percent change in muscle fat infiltration for those randomized to liraglutide was -2.87% from baseline, and 0.05% in the placebo arm (absolute change: -0.23% vs. 0.01%). Additionally, a weight-invariant assessment of muscle volume was performed using AMRA’s muscle volume z-score did not show a significant reduction comparing liraglutide to placebo (mean treatment difference adjusted for baseline muscle volume z-score was -0.08 standard deviations). The study also uncovered that the proportion of participants with adverse muscle composition dropped from 11.0% to 8.2% over follow-up in the liraglutide arm, while no change in the placebo arm was observed.
While the contribution of muscle fat infiltration improvement to the cardiometabolic benefits of liraglutide requires further investigation, the above findings come at a critical time given the global rise of obesity incidence and its comorbidities posing more of a threat to patients than ever before. As the treatment paradigm begins to shift from solely lifestyle changes to one that includes pharmacological intervention (namely the popular GLP-1 agonists such as liraglutide) and drug development in obesity ramps up, it is paramount that these drugs are accurately assessed for their impact on muscle composition to ensure that the weight loss they help to achieve does not result in adverse effects on muscle health.
Through their gold-standard MRI-based body composition analysis technology, AMRA is committed to pioneering the creation of normative datasets explaining the effect of GLP-1s and incretin-based treatments on muscle composition to help the obesity field gain further insight as to how these drugs work in this relatively new indication. Recently, AMRA presented related findings at the 59th European Association for the Study of Diabetes Annual Meeting, where it was shown that another popular GLP-1, tirzepatide, achieved significant weight loss without any adverse effects on muscle composition. You can view the presentation here.
Learn more about AMRA Medical and how the use of MRI-based body composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502719692/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release
Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic
An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom